Evidence map›Paper›PMID 31065045›Full record

ReviewNature reviews. Cardiology2019

70-year legacy of the Framingham Heart Study.

Charlotte Andersson, Andrew D Johnson, Emelia J Benjamin, Daniel Levy, Ramachandran S Vasan

Abstract readHistorical ArticleReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed
19.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 297 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. An epigenetic speedometer to measure Pace of Aging: FraminghamPACE.medRxiv : the preprint server for health sciences · 2026
    Article
  5. Observational
  6. Review
  7. Review
  8. Influence of an AQP4 haplotype and sleep duration on early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Article
  10. Relevance and challenges of exposome studies for environmental health research.Environmental health : a global access science source · 2026
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Charlotte AnderssonBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA. ca@heart.dk.
Andrew D JohnsonBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA.
Emelia J BenjaminBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA.ORCID http://orcid.org/0000-0003-4076-2336
Daniel LevyBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA.
Ramachandran S VasanBoston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA. vasan@bu.edu.ORCID http://orcid.org/0000-0001-7357-5970
Boston University · USHerlev Hospital · DKNational Heart Lung and Blood Institute · US

Funding

Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1M
Cardiovascular Genomics and Bioinformatics projectsZIAHL006170 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI JOHNSON, ANDREW · 2013 to 2025
$25.3M
6 · The paper itself

Abstract

The Framingham Heart Study (FHS) was established in 1948 to improve understanding of the epidemiology of coronary heart disease (CHD) in the USA. In 1961, seminal work identified major risk factors for CHD (high blood pressure, high cholesterol levels and evidence on the electrocardiogram of left ventricular hypertrophy), which later formed the basis for multivariable 10-year and 30-year risk-prediction algorithms. The FHS cohorts now comprise three generations of participants (n ≈ 15,000) and two minority cohorts. The FHS cohorts are densely phenotyped, with recurring follow-up examinations and surveillance for cardiovascular and non-cardiovascular end points. Assessment of subclinical disease and physiological profiling of these cohorts (with the use of echocardiography, ambulatory electrocardiographic monitoring, exercise stress testing, cardiac CT, heart and brain MRI, serial vascular tonometry and accelerometry) have been performed repeatedly. Over the past decade, the FHS cohorts have undergone deep 'omics' profiling (including whole-genome sequencing, DNA methylation analysis, transcriptomics, high-throughput proteomics and metabolomics, and microbiome studies). The FHS is a rich, longitudinal, transgenerational and deeply phenotyped cohort study with a sustained focus on state-of-the-art epidemiological methods and technological advances to facilitate scientific discoveries.

Indexed as

Longitudinal StudiesPopulation SurveillanceCardiovascular DiseasesCoronary Artery DiseaseData CollectionEchocardiographyExercise TestGenomicsHistory, 20th CenturyHistory, 21st CenturyHumansMagnetic Resonance ImagingManometryPhenotypeRisk FactorsTomography, X-Ray Computed

Identifiers

PMID31065045
OpenAlexW2944646092

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.